Fibrodysplasia Ossificans Progressiva Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major fibrodysplasia ossificans progressiva markets reached a value of US$ 361.2 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 503.8 Million by 2034, exhibiting a growth rate (CAGR) of 3.07% during 2024-2034.
The fibrodysplasia ossificans progressiva market has been comprehensively analyzed in IMARC's new report titled "Fibrodysplasia Ossificans Progressiva Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Fibrodysplasia ossificans progressiva (FOP) refers to an extremely rare and debilitating genetic disorder characterized by the abnormal ossification or formation of bone in soft tissues, such as muscles, tendons, and ligaments. It is caused by a mutation in the ACVR1 gene, leading to the inappropriate activation of bone morphogenetic protein (BMP) receptors. The symptoms of this condition usually manifest in early childhood and progressively worsen over time. Initially, patients may develop benign soft tissue swellings, known as flare-ups, which are painful and often lead to immobility. As the disease advances, these flare-ups transform into heterotopic ossification, causing joints to fuse. This results in a severely limited range of motion and significant impairment in daily activities. Diagnosing FOP is primarily based on clinical presentation, medical history, and genetic testing to identify the gene mutation. However, given its rarity and potential for misdiagnosis, it is important for healthcare professionals to be aware of its distinctive features and differentiate it from various other conditions presenting with similar symptoms.
The escalating incidence of somatic mutations in the ACVR1 gene that can lead to the overactivation of a certain receptor in the body, causing the development of abnormal bone in muscles, tendons, and ligaments, is primarily driving the fibrodysplasia ossificans progressiva market. In addition to this, the inflating utilization of effective treatments, such as glucocorticoids and non-steroidal anti-inflammatory drugs (NSAIDs), which aim to control inflammation and mitigate the formation of heterotopic ossification in patients, is also creating a positive outlook for the market. Moreover, the widespread adoption of physical and occupational therapies due to their valuable role in maintaining muscle function, enhancing joint mobility, and managing pain is further bolstering the market growth. Apart from this, the rising usage of surgical interventions and the development of minimally invasive techniques to address disease complications, like joint ankylosis and breathing difficulties, are acting as another significant growth-inducing factor. These surgical procedures, including the excision of ectopic bones, help to restore functional movement and reduce pain in severely affected patients. Additionally, the emerging popularity of gene therapy, since it offers the possibility of correcting the faulty genetic material, thereby halting or even reversing the progression of the illness, is expected to drive the fibrodysplasia ossificans progressiva market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the fibrodysplasia ossificans progressiva market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for fibrodysplasia ossificans progressiva and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the fibrodysplasia ossificans progressiva market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the fibrodysplasia ossificans progressiva market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the fibrodysplasia ossificans progressiva market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current fibrodysplasia ossificans progressiva marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the fibrodysplasia ossificans progressiva market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the fibrodysplasia ossificans progressiva market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the fibrodysplasia ossificans progressiva market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of fibrodysplasia ossificans progressiva across the seven major markets?
What is the number of prevalent cases (2018-2034) of fibrodysplasia ossificans progressiva by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of fibrodysplasia ossificans progressiva by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with fibrodysplasia ossificans progressiva across the seven major markets?
What is the size of the fibrodysplasia ossificans progressiva patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of fibrodysplasia ossificans progressiva?
What will be the growth rate of patients across the seven major markets?
Fibrodysplasia Ossificans Progressiva: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for fibrodysplasia ossificans progressiva drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the fibrodysplasia ossificans progressiva market?
What are the key regulatory events related to the fibrodysplasia ossificans progressiva market?
What is the structure of clinical trial landscape by status related to the fibrodysplasia ossificans progressiva market?
What is the structure of clinical trial landscape by phase related to the fibrodysplasia ossificans progressiva market?
What is the structure of clinical trial landscape by route of administration related to the fibrodysplasia ossificans progressiva market?
The fibrodysplasia ossificans progressiva market has been comprehensively analyzed in IMARC's new report titled "Fibrodysplasia Ossificans Progressiva Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Fibrodysplasia ossificans progressiva (FOP) refers to an extremely rare and debilitating genetic disorder characterized by the abnormal ossification or formation of bone in soft tissues, such as muscles, tendons, and ligaments. It is caused by a mutation in the ACVR1 gene, leading to the inappropriate activation of bone morphogenetic protein (BMP) receptors. The symptoms of this condition usually manifest in early childhood and progressively worsen over time. Initially, patients may develop benign soft tissue swellings, known as flare-ups, which are painful and often lead to immobility. As the disease advances, these flare-ups transform into heterotopic ossification, causing joints to fuse. This results in a severely limited range of motion and significant impairment in daily activities. Diagnosing FOP is primarily based on clinical presentation, medical history, and genetic testing to identify the gene mutation. However, given its rarity and potential for misdiagnosis, it is important for healthcare professionals to be aware of its distinctive features and differentiate it from various other conditions presenting with similar symptoms.
The escalating incidence of somatic mutations in the ACVR1 gene that can lead to the overactivation of a certain receptor in the body, causing the development of abnormal bone in muscles, tendons, and ligaments, is primarily driving the fibrodysplasia ossificans progressiva market. In addition to this, the inflating utilization of effective treatments, such as glucocorticoids and non-steroidal anti-inflammatory drugs (NSAIDs), which aim to control inflammation and mitigate the formation of heterotopic ossification in patients, is also creating a positive outlook for the market. Moreover, the widespread adoption of physical and occupational therapies due to their valuable role in maintaining muscle function, enhancing joint mobility, and managing pain is further bolstering the market growth. Apart from this, the rising usage of surgical interventions and the development of minimally invasive techniques to address disease complications, like joint ankylosis and breathing difficulties, are acting as another significant growth-inducing factor. These surgical procedures, including the excision of ectopic bones, help to restore functional movement and reduce pain in severely affected patients. Additionally, the emerging popularity of gene therapy, since it offers the possibility of correcting the faulty genetic material, thereby halting or even reversing the progression of the illness, is expected to drive the fibrodysplasia ossificans progressiva market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the fibrodysplasia ossificans progressiva market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for fibrodysplasia ossificans progressiva and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the fibrodysplasia ossificans progressiva market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the fibrodysplasia ossificans progressiva market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the fibrodysplasia ossificans progressiva market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current fibrodysplasia ossificans progressiva marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the fibrodysplasia ossificans progressiva market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the fibrodysplasia ossificans progressiva market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the fibrodysplasia ossificans progressiva market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of fibrodysplasia ossificans progressiva across the seven major markets?
What is the number of prevalent cases (2018-2034) of fibrodysplasia ossificans progressiva by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of fibrodysplasia ossificans progressiva by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with fibrodysplasia ossificans progressiva across the seven major markets?
What is the size of the fibrodysplasia ossificans progressiva patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of fibrodysplasia ossificans progressiva?
What will be the growth rate of patients across the seven major markets?
Fibrodysplasia Ossificans Progressiva: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for fibrodysplasia ossificans progressiva drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the fibrodysplasia ossificans progressiva market?
What are the key regulatory events related to the fibrodysplasia ossificans progressiva market?
What is the structure of clinical trial landscape by status related to the fibrodysplasia ossificans progressiva market?
What is the structure of clinical trial landscape by phase related to the fibrodysplasia ossificans progressiva market?
What is the structure of clinical trial landscape by route of administration related to the fibrodysplasia ossificans progressiva market?
?1 Preface
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 FIBRODYSPLASIA OSSIFICANS PROGRESSIVA - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 FIBRODYSPLASIA OSSIFICANS PROGRESSIVA - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 FIBRODYSPLASIA OSSIFICANS PROGRESSIVA - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 FIBRODYSPLASIA OSSIFICANS PROGRESSIVA - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 FIBRODYSPLASIA OSSIFICANS PROGRESSIVA - UNMET NEEDS
10 FIBRODYSPLASIA OSSIFICANS PROGRESSIVA - KEY ENDPOINTS OF TREATMENT
11 FIBRODYSPLASIA OSSIFICANS PROGRESSIVA - MARKETED PRODUCTS
11.1 List of Fibrodysplasia Ossificans Progressiva Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name – Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the complete list of marketed drugs has been provided in the report.
12 FIBRODYSPLASIA OSSIFICANS PROGRESSIVA - PIPELINE DRUGS
12.1 List of Fibrodysplasia Ossificans Progressiva Pipeline Drugs Across the Top 7 Markets
12.1.1 IPN 60130 - Ipsen
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 INCB 000928 - Incyte Corporation
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 Garetosmab - Regeneron Pharmaceuticals
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 Palovarotene - Clementia Pharmaceuticals
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
12.1.5 DS 6016a - Daiichi Sankyo
12.1.5.1 Drug Overview
12.1.5.2 Mechanism of Action
12.1.5.3 Clinical Trial Results
12.1.5.4 Safety and Efficacy
12.1.5.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. FIBRODYSPLASIA OSSIFICANS PROGRESSIVA - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. FIBRODYSPLASIA OSSIFICANS PROGRESSIVA – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 FIBRODYSPLASIA OSSIFICANS PROGRESSIVA - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Fibrodysplasia Ossificans Progressiva - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Fibrodysplasia Ossificans Progressiva - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Fibrodysplasia Ossificans Progressiva - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Fibrodysplasia Ossificans Progressiva - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Fibrodysplasia Ossificans Progressiva - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Fibrodysplasia Ossificans Progressiva - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Fibrodysplasia Ossificans Progressiva - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Fibrodysplasia Ossificans Progressiva - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Fibrodysplasia Ossificans Progressiva - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Fibrodysplasia Ossificans Progressiva - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Fibrodysplasia Ossificans Progressiva - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Fibrodysplasia Ossificans Progressiva - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Fibrodysplasia Ossificans Progressiva - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Fibrodysplasia Ossificans Progressiva - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Fibrodysplasia Ossificans Progressiva - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Fibrodysplasia Ossificans Progressiva - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Fibrodysplasia Ossificans Progressiva - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Fibrodysplasia Ossificans Progressiva - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Fibrodysplasia Ossificans Progressiva - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Fibrodysplasia Ossificans Progressiva - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Fibrodysplasia Ossificans Progressiva - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Fibrodysplasia Ossificans Progressiva - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Fibrodysplasia Ossificans Progressiva - Access and Reimbursement Overview
16 FIBRODYSPLASIA OSSIFICANS PROGRESSIVA - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 FIBRODYSPLASIA OSSIFICANS PROGRESSIVA - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 FIBRODYSPLASIA OSSIFICANS PROGRESSIVA - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 FIBRODYSPLASIA OSSIFICANS PROGRESSIVA - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 FIBRODYSPLASIA OSSIFICANS PROGRESSIVA - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 FIBRODYSPLASIA OSSIFICANS PROGRESSIVA - UNMET NEEDS
10 FIBRODYSPLASIA OSSIFICANS PROGRESSIVA - KEY ENDPOINTS OF TREATMENT
11 FIBRODYSPLASIA OSSIFICANS PROGRESSIVA - MARKETED PRODUCTS
11.1 List of Fibrodysplasia Ossificans Progressiva Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name – Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the complete list of marketed drugs has been provided in the report.
12 FIBRODYSPLASIA OSSIFICANS PROGRESSIVA - PIPELINE DRUGS
12.1 List of Fibrodysplasia Ossificans Progressiva Pipeline Drugs Across the Top 7 Markets
12.1.1 IPN 60130 - Ipsen
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 INCB 000928 - Incyte Corporation
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 Garetosmab - Regeneron Pharmaceuticals
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 Palovarotene - Clementia Pharmaceuticals
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
12.1.5 DS 6016a - Daiichi Sankyo
12.1.5.1 Drug Overview
12.1.5.2 Mechanism of Action
12.1.5.3 Clinical Trial Results
12.1.5.4 Safety and Efficacy
12.1.5.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. FIBRODYSPLASIA OSSIFICANS PROGRESSIVA - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. FIBRODYSPLASIA OSSIFICANS PROGRESSIVA – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 FIBRODYSPLASIA OSSIFICANS PROGRESSIVA - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Fibrodysplasia Ossificans Progressiva - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Fibrodysplasia Ossificans Progressiva - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Fibrodysplasia Ossificans Progressiva - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Fibrodysplasia Ossificans Progressiva - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Fibrodysplasia Ossificans Progressiva - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Fibrodysplasia Ossificans Progressiva - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Fibrodysplasia Ossificans Progressiva - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Fibrodysplasia Ossificans Progressiva - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Fibrodysplasia Ossificans Progressiva - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Fibrodysplasia Ossificans Progressiva - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Fibrodysplasia Ossificans Progressiva - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Fibrodysplasia Ossificans Progressiva - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Fibrodysplasia Ossificans Progressiva - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Fibrodysplasia Ossificans Progressiva - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Fibrodysplasia Ossificans Progressiva - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Fibrodysplasia Ossificans Progressiva - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Fibrodysplasia Ossificans Progressiva - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Fibrodysplasia Ossificans Progressiva - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Fibrodysplasia Ossificans Progressiva - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Fibrodysplasia Ossificans Progressiva - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Fibrodysplasia Ossificans Progressiva - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Fibrodysplasia Ossificans Progressiva - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Fibrodysplasia Ossificans Progressiva - Access and Reimbursement Overview
16 FIBRODYSPLASIA OSSIFICANS PROGRESSIVA - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
